ProMab Biotechnologies has a collection of >3,000 antibody products. The high-throughput flow cytometric screening of hybridomas identifies high-binding antibodies for immunotherapeutics.
From the development of an antibody hybridoma, we are able to sequence and isolate the scFv sequence.
The scFv sequence is inserted into a lentiviral vector along with CAR domains of your choosing. High- titer virus particles are prepared and titered by qRT-PCR.
Primary T cells are activated, transduced by the CAR-encoding lentivirus and expanded in culture for two weeks. ProMab has generated >30 types of CAR-T cells and target cells.
The RTCA assay provides highly sensitive real-time measurements of CAR-T cell cytotoxicity against target cells at different E:T ratios. CAR-T cells produce IFN-γ and other cytokines in response to target cells.
Label-free high-throughput Octet ForteBio binding assays. Affinity maturation and humanization of antibodies are available to increase antibody affinity. Bioinformatics and computer modeling generate humanized and affinity-tuned antibodies.
NSG/NOG xenograft survival and imaging studies characterize CAR-T cells in vivo. Toxicology tests measure the toxicity of the CAR-T cells in vivo.
ProMab manufactures QA-validated CAR-T cells and access to GMP facilities.